Maxim Group Keeps Their Buy Rating on Femasys (FEMY)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Femasys (FEMYResearch Report), with a price target of $5.00. The company’s shares opened today at $1.06.

According to TipRanks, McCarthy is an analyst with an average return of -37.2% and a 15.33% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Lineage Cell Therapeutics.

Currently, the analyst consensus on Femasys is a Strong Buy with an average price target of $7.33.

See today’s best-performing stocks on TipRanks >>

Based on Femasys’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $347.46 thousand and a GAAP net loss of $2.98 million. In comparison, last year the company earned a revenue of $269.58 thousand and had a GAAP net loss of $2.26 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Femasys Inc is a biomedical company focused on transforming women’s healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.

Read More on FEMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More